PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
PHASE2
PHOENIX is a window of opportunity (WOP), open-label, multi-centre, phase I...
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
PHASE2
This phase II trial studies how well olaparib works in treating patients wi...
Status
Active Not Recruiting
Location
UC Irvine Health/Chao Family Comprehensive Cancer Center